• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Nutrients >Circulating Levels of the Soluble Receptor for AGE (sRAGE) during Escalating Oral Glucose Dosages and Corresponding Isoglycaemic i.v. Glucose Infusions in Individuals with and without Type 2 Diabetes
【2h】

Circulating Levels of the Soluble Receptor for AGE (sRAGE) during Escalating Oral Glucose Dosages and Corresponding Isoglycaemic i.v. Glucose Infusions in Individuals with and without Type 2 Diabetes

机译：在升级口服葡萄糖剂量和相应的异丙糖I.V期间循环溶于溶于溶于溶于患者（SRAGE）的水平和相应的异丙糖。葡萄糖输注在没有2型糖尿病的情况下

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Postprandial glucose excursions are postulated to increase the risk for diabetes complications via the production of advanced glycation end products (AGEs). The soluble receptor of AGEs (sRAGE) likely acts as a decoy receptor, mopping up AGEs, diminishing their capacity for pro-inflammatory and pro-apoptotic signaling. Recent evidence suggests that AGEs and soluble receptor for AGEs (sRAGE) may be altered under postprandial and fasting conditions. Here, we investigated the effects of increasing oral glucose loads during oral glucose tolerance tests (OGTT) and matched isoglycaemic intravenous (i.v.) glucose infusions (IIGI) on circulating concentrations of sRAGE. Samples from eight individuals with type 2 diabetes and eight age-, gender-, and body mass index (BMI)-matched controls, all of whom underwent three differently dosed OGTTs (25 g, 75 g, and 125 g), and three matched IIGIs were utilised ({"type":"clinical-trial","attrs":{"text":"NCT00529048","term_id":"NCT00529048"}}NCT00529048). Serum concentrations of sRAGE were measured over 240 min during each test. For individuals with diabetes, sRAGE area under the curve (AUC0–240min) declined with increasing i.v. glucose dosages (p < 0.0001 for trend) and was lower during IIGI compared to OGTT at the 125 g dosage (p = 0.004). In control subjects, sRAGE AUC0–240min was only lower during IIGI compared to OGTT at the 25 g dose (p = 0.0015). sRAGE AUC0–240min was negatively correlated to AUC0–240min for the incretin hormone glucagon-like peptide −1 (GLP-1) during the 75 g OGTT and matched IIGI, but only in individuals with type 2 diabetes. These data suggest that gastrointestinal factors may play a role in regulating sRAGE concentrations during postprandial glucose excursions, thus warranting further investigation.
机译：后葡萄糖偏移假设通过生产先进的糖糖末期产品（年龄）增加糖尿病并发症的风险。年龄（SRAGE）的可溶性受体可能用作诱饵受体，造成摩托车，缩短其促炎和促凋亡信号传导的能力。最近的证据表明，年龄（SRAGE）的年龄和可溶性受体可能会在餐后和禁食条件下改变。在这里，我们研究了口服葡萄糖耐量试验（OGTT）和匹配的异血静脉注射（I.V.）葡萄糖输注（IIGI）对循环血管浓度的影响。来自八种糖尿病的八种和八种年龄，性别和体重指数（BMI）的样品 - 所有患有3种不同的糖尿病对照，其中所有患有三种不同剂量的OGTTS（25克，75克和125克）和三种匹配利用Igis（{“类型”：“临床试验”，“attrs”：{“text”：“nct00529048”，“term_id”：“nct00529048”}} NCT00529048）。在每次试验期间240分钟测量血清浓度的SRAGE。对于患有糖尿病的个体，曲线下的SRAGE面积（AUC0-240Min）随着I.V的增加而下降。与125g剂量的OGTT相比，葡萄糖剂量（P <0.0001用于趋势），在IgI中较低（P = 0.004）。在对照主题中，SRAGE AUC0-240与25g剂量的OGTT相比，分钟仅在IgI期间较低（P = 0.0015）。 SRAGE AUC0-240分钟与AUC0-240负相关在75克ogtt和匹配的Igi期间，在胰腈激素胰高血糖素样肽-1（GLP-1），但仅在2型糖尿病的个体中。这些数据表明，胃肠因子可能在治疗后血糖偏移期间调节血管浓度的作用，从而需要进一步调查。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号